Charlotte Aaquist Haslund

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

B.J. Monk, Maria Pilar Barretina-Ginesta, Bhavana Pothuri et al. · Annals of Oncology · 2024 · 150 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

Ignace Vergote, Bente Lund, Ulla Peen et al. · Gynecologic Oncology · 2019 · 48 citations

Medicine, Oncology, Pharmacology +9

The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients

Inge Marie Svane, Henrik Schmidt, Charlotte Aaquist Haslund et al. · Cancer Epidemiology · 2021 · 43 citations · Full text

Medicine, Biomedical Informatics, Oncology +17

PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma

Shawez Khan, Lars Bastholt, Henrik Schmidt et al. · European Journal of Cancer · 2023 · 35 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6)

Ursula A. Matulonis, Jørn Herrstedt, Amit M. Oza et al. · Gynecologic Oncology · 2023 · 32 citations · Full text

Medicine, Gynecology, Oncology +15